ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1704

Identifying Primary Care Clinician Knowledge Gaps and Needs in Rheumatologic Care for Rural Veterans
Abstract Number: 1705

In-Person Musculoskeletal Exam Demonstration by Rheumatologist More Effective Than Virtual PowerPoint Presentation in Teaching Internal Medicine Residents
Abstract Number: 1706

Advanced Integrated Science Courses: A Novel Approach to Medical Student Science Education
Abstract Number: 1707

Development and Delivery of Continuing Education Interventions Promoting Shared Decision Making in Rheumatoid Arthritis
Abstract Number: 1708

Itching to Learn: Infusion Reactions Curriculum for Medicine Trainees
Abstract Number: 1709

Teaching Clinical Application of Bayesian Reasoning in Rheumatology to Internal Medicine Residents and Medical Students
Abstract Number: 1710

Remote Rheumapalooza: Reboot of a Foundational Rheumatology Curriculum for Pre-Clinical Medical Students in the Era of Virtual Learning
Abstract Number: 1711

Musculoskeletal Sarcoidosis Learning Module for Internal Medicine Trainees: Developing a Rheumatology Curriculum
Abstract Number: 1712

Implementation of a Musculoskeletal Ultrasound (MSUS) Curriculum in an Academic Rheumatology Fellowship Within an Integrated Health System: A Four-Year Experience
Abstract Number: 1713

Exploring Novel Tenosynovitis and Combined Inflammation Imaging Outcomes: Results from a Randomized Controlled Trial in Early Rheumatoid Arthritis
Abstract Number: 1714

Disease Activity Trajectories for Early and Established Rheumatoid Arthritis: Real World Results from a Rheumatoid Arthritis Cohort
Abstract Number: 1715

Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)
Abstract Number: 1716

Predictors of Unacceptable Pain and Unacceptable Pain with Low Inflammation in Early Rheumatoid Arthritis
Abstract Number: 1717

Impact of Treatments on Favorable Outcome over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort
Abstract Number: 1718

Impact of Treatments on Radiographic Progression over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].